New Nimodipine Formulation Aimed At Reducing Fatal Medication Errors
This article was originally published in The Pink Sheet Daily
Executive Summary
Nymalize, an oral formulation of brain hemorrhage treatment nimodipine, aims to minimize serious risks associated with incorrect administration of older forms of the drug.
You may also be interested in...
Arbor Emphasizes Risks Of Its Own Product In Suit Against US FDA To Block Nymalize Generics
FDA concluded that original formulation of brain hemorrhage treatment was not discontinued for safety or effectiveness reasons, saying Arbor had other options to reduce risk of confusion between the new and original formulations. But the sponsor argues that withdrawal was part of FDA-approved risk mitigation plan.
Edge 'Devastated' By Phase III Failure of EG-1962, Set To Downsize
Company announces plans for layoffs after Phase III NEWTON 2 study of EG-1962 for subarachnoid hemorrhage goes up in smoke.
FDA's Drug Safety Oversight Board Looks To Promote Its Value
FDA's Drug Safety Oversight Board is trying to promote its value to the medical and regulatory communities by highlighting its role in addressing postmarketing safety issues